내시경 역행 췌담관 조영술 시장 규모, 점유율, 동향 분석 보고서 : 제품 유형별, 시술 유형별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

Market Size & Trends:

The global endoscopic retrograde cholangiopancreatography market size was estimated at USD 2.17 billion in 2024 and is anticipated to grow at a CAGR of 8.26% from 2025 to 2030. This growth is majorly driven by the rising incidence of pancreatic and biliary diseases such as gallstones, pancreatitis, and bile duct obstructions are fueling the demand for ERCP procedures. As the population ages and lifestyles change, the prevalence of these conditions is expected to increase, driving market growth. According to Clinical Gastroenterology and Hepatology study published in February 2024, there is an estimated 6% prevalence of gallstones globally, with higher rates observed in females and in South America. According to studies, the incidence rate of gallstones is anticipated to rise sharply over the forecast period, thereby driving the demand for endoscopic retrograde cholangiopancreatography (ERCP) procedures.

Furthermore, advances in endoscopic technology have improved the safety and efficacy of ERCP procedures. For instance, in January 2023, Advantech introduced the MIO-5377R single board computer as a groundbreaking innovation in the field of endoscope technology. This compact and powerful device is designed to address the traditional challenges faced by endoscopes, offering enhanced performance, reliability, and functionality. Moreover, innovations such as high-definition imaging, better maneuverability of endoscopes, and the development of therapeutic accessories have made ERCP a more precise and effective diagnostic and treatment tool. These technological advancements are attracting both healthcare providers and patients to opt for ERCP procedures.

The rise in the adoption of minimally invasive surgical techniques has led to an increased demand for ERCP procedures, which is expected to drive growth in the industry in the upcoming years. For instance, according to the American Cancer Society's annual report published in January 2024, an estimated 41,630 new cases of liver cancer are expected to be diagnosed in the U.S. Additionally, as per the same source, liver cancer is more prevalent in countries in sub- Southeast Asia and Saharan Africa compared to the U.S. It is the most common type of cancer in many of these nations, with over 800,000 new cases diagnosed globally each year. Additionally, liver cancer ranks as a leading cause of cancer-related deaths worldwide, claiming more than 700,000 lives annually.

The high burden of cholangiocarcinoma and hepatocellular carcinoma is expected to boost the demand for endoscopic retrograde cholangiopancreatography for the early detection of such malignancies.

Moreover, the increased awareness about the benefits of early diagnosis and treatment of pancreatic and biliary diseases has led to a higher demand for minimally invasive procedures such as ERCP. For instance, in October 2023. the Biliary Atresia Awareness Committee launched Biliary Atresia Awareness Campaign under the auspices of Gauteng Provincial Solid Organ Transplant Division and the University of the Witwatersrand at Charlotte Maxeke Academic Hospital. The campaign was aimed to raise awareness and support for children affected by biliary atresia, a rare and life-threatening liver disease that affects infants by obstructing or obliterating bile ducts. The initiative was focused on educating diverse demographics about biliary atresia, offering resources and support to affected families, advancing research for diagnostic tools and treatments, and fostering collaboration with medical entities globally.

The aging population is a significant factor driving the growth of the endoscopic retrograde cholangiopancreatography market. As the global population continues to age, there is a growing demand for these procedures, including surgeries that require blood transfusions. Chronic diseases such as caugulopathy, anemia, and surgical blood seeking continue to increase along with the increase in adult population. Currently , there are over 40 million people in the U.S. alone above 65 years and the number are expected to double by 2050. Japan provides potential growth opportunities to this market due to the presence of the highest geriatric population in the globe. According to WHO, the percentage of the geriatric population is expected to reach 22.0% by 2050.

Additionally, several healthcare organizations are adopting initiatives including partnerships for the R&D of innovative products, thereby fueling the market growth. For instance , according to research study published in Optica Publishing Group journal in July 2022, researchers at the School of Biomedical Engineering & Imaging Sciences developed a photoacoustic imaging endoscope probe which can be inserted into a medical needle with an inner diameter as small as 0.6 millimeters. They also suggested that artificial intelligence (AI) could be utilized to accelerate imaging procedures.

Furthermore, the strategic initiatives adopted by the market players, such as mergers, and acquisitions, and product launches are projected to drive the market over the forecast period. For instance, in April 2022, Olympus partnered with EndoClot Plus, a company that focuses on developing technologies in the hemostasis space. One of the key products in EndoClot Plus' portfolio is the EndoClot PHS, a nonthermal, nontraumatic method for achieving hemostasis with gastrointestinal (GI) bleeds. This agreement aims to make the EndoClot PHS more accessible to gastroenterologists, enabling them to stop bleeding rapidly and reliably during medical procedures.

Global Endoscopic Retrograde Cholangiopancreatography Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global endoscopic retrograde cholangiopancreatography market report based on product, procedure, end use and region:

• Product Outlook (Revenue, USD Million, 2018 - 2030)
• Endoscopes
• Endotherapy Devices
  • Sphincterotomes
  • Lithotripter
  • Stents
  • Cannulas
  • Forceps
  • Snares
  • Catheters
  • Guiding Wires
  • Balloons
  • Baskets
• Visualization Systems
• Energy Devices
• Others
• Procedure Outlook (Revenue, USD Million, 2018 - 2030)
• Biliary Sphincterotomy
• Biliary Stenting
• Biliary Dilatation
• Pancreatic Sphincterotomy
• Pancreatic Duct Stenting
• Pancreatic Duct Dilation
• End use Outlook (Revenue, USD Million, 2018 - 2030)
• Hospitals
• Outpatient Facilities
• Regional Outlook (Revenue, USD Million, 2018 - 2030)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Norway
  • Sweden
  • Denmark
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Procedure
  • 1.2.3. End use
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product outlook
  • 2.2.2. Procedure outlook
  • 2.2.3. End use outlook
• 2.3. Regional outlook
• 2.4. Competitive Insights

Chapter 3. Endoscopic Retrograde Cholangiopancreatography Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Endoscopic Retrograde Cholangiopancreatography Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Bargaining power of suppliers
    • 3.3.1.2. Bargaining power of buyers
    • 3.3.1.3. Threat of substitutes
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic landscape
    • 3.3.2.3. Social landscape
    • 3.3.2.4. Technological landscape
    • 3.3.2.5. Environmental landscape
    • 3.3.2.6. Legal landscape

Chapter 4. Endoscopic Retrograde Cholangiopancreatography Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Endoscopic Retrograde Cholangiopancreatography Market: Product Movement Analysis
• 4.3. Endoscopic Retrograde Cholangiopancreatography Market by Product Outlook (USD Million)
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 4.5. Endoscopes
  • 4.5.1. Endoscopes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.6. Endotherapy Devices
  • 4.6.1. Endotherapy Devices Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6.2. Sphincterotomes
    • 4.6.2.1. Sphincterotomes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6.3. Lithotripter
    • 4.6.3.1. Lithotripter Market Revenue Estimates and Fo recasts, 2018 - 2030 (USD Million)
  • 4.6.4. Stents
    • 4.6.4.1. Stents Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6.5. Cannulas
    • 4.6.5.1. Cannulas Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6.6. Forceps
    • 4.6.6.1. Forceps Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6.7. Snares
    • 4.6.7.1. Snares Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6.8. Catheters
    • 4.6.8.1. Catheters Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6.9. Guiding Wires
    • 4.6.9.1. Guiding Wires Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6.10. Balloons
    • 4.6.10.1. Balloons Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6.11. Baskets
    • 4.6.11.1. Baskets Stents Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.7. Visualization Systems
  • 4.7.1. Visualization Systems Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.8. Energy Devices
  • 4.8.1. Energy Devices Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.9. Others
  • 4.9.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Endoscopic Retrograde Cholangiopancreatography Market: Procedure Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Endoscopic Retrograde Cholangiopancreatography Market: Procedure Movement Analysis
• 5.3. Endoscopic Retrograde Cholangiopancreatography Market by Procedure Outlook (USD Million)
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 5.5. Biliary Sphincterotomy
  • 5.5.1. Biliary Sphincterotomy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.6. Biliary Stenting
  • 5.6.1. Biliary Stenting Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.7. Biliary Dilatation
  • 5.7.1. Biliary Dilatation Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.8. Pancreatic Sphincterotomy
  • 5.8.1. Pancreatic Sphincterotomy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.9. Pancreatic Duct Stenting
  • 5.9.1. Pancreatic Duct Stenting Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.10. Pancreatic Duct Dilation
  • 5.10.1. Pancreatic Duct Dilation Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Endoscopic Retrograde Cholangiopancreatography Market: End use Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Endoscopic Retrograde Cholangiopancreatography Market: End use Movement Analysis
• 6.3. Endoscopic Retrograde Cholangiopancreatography Market by End use Outlook (USD Million)
• 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 6.5. Hospitals
  • 6.5.1. Hospitals Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.6. Outpatient Facilities
  • 6.6.1. Outpatient Facilities Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Endoscopic Retrograde Cholangiopancreatography Market: Regional Estimates & Trend Analysis

• 7.1. Regional Dashboard
• 7.2. Regional Endoscopic Retrograde Cholangiopancreatography Market movement analysis
• 7.3. Endoscopic Retrograde Cholangiopancreatography Market: Regional Estimates & Trend Analysis by Technology & End use
• 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 7.5. North America
  • 7.5.1. North America Endoscopic Retrograde Cholangiopancreatography Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.2. U.S.
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Competitive Scenario
    • 7.5.2.3. Regulatory Framework
    • 7.5.2.4. Reimbursement scenario
    • 7.5.2.5. U.S. Endoscopic Retrograde Cholangiopancreatography Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.3. Canada
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Competitive Scenario
    • 7.5.3.3. Regulatory Framework
    • 7.5.3.4. Reimbursement scenario
    • 7.5.3.5. Canada Endoscopic Retrograde Cholangiopancreatography Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.4. Mexico
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Competitive Scenario
    • 7.5.4.3. Regulatory Framework
    • 7.5.4.4. Reimbursement scenario
    • 7.5.4.5. Mexico Endoscopic Retrograde Cholangiopancreatography Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.5. Europe
  • 7.5.6. Europe Endoscopic Retrograde Cholangiopancreatography Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.7. UK
    • 7.5.7.1. Key Country Dynamics
    • 7.5.7.2. Competitive Scenario
    • 7.5.7.3. Regulatory Framework
    • 7.5.7.4. Reimbursement scenario
    • 7.5.7.5. UK Endoscopic Retrograde Cholangiopancreatography Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.8. Germany
    • 7.5.8.1. Key Country Dynamics
    • 7.5.8.2. Competitive Scenario
    • 7.5.8.3. Regulatory Framework
    • 7.5.8.4. Reimbursement scenario
    • 7.5.8.5. Germany Endoscopic Retrograde Cholangiopancreatography Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.9. France
    • 7.5.9.1. Key Country Dynamics
    • 7.5.9.2. Competitive Scenario
    • 7.5.9.3. Regulatory Framework
    • 7.5.9.4. Reimbursement scenario
    • 7.5.9.5. France Endoscopic Retrograde Cholangiopancreatography Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.10. Italy
    • 7.5.10.1. Key Country Dynamics
    • 7.5.10.2. Competitive Scenario
    • 7.5.10.3. Regulatory Framework
    • 7.5.10.4. Reimbursement scenario
    • 7.5.10.5. Italy Endoscopic Retrograde Cholangiopancreatography Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.11. Spain
    • 7.5.11.1. Key Country Dynamics
    • 7.5.11.2. Competitive Scenario
    • 7.5.11.3. Regulatory Framework
    • 7.5.11.4. Reimbursement scenario
    • 7.5.11.5. Spain Endoscopic Retrograde Cholangiopancreatography Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.12. Denmark
    • 7.5.12.1. Key Country Dynamics
    • 7.5.12.2. Competitive Scenario
    • 7.5.12.3. Regulatory Framework
    • 7.5.12.4. Reimbursement scenario
    • 7.5.12.5. Denmark Endoscopic Retrograde Cholangiopancreatography Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.13. Sweden
    • 7.5.13.1. Key Country Dynamics
    • 7.5.13.2. Competitive Scenario
    • 7.5.13.3. Regulatory Framework
    • 7.5.13.4. Reimbursement scenario
    • 7.5.13.5. Sweden Endoscopic Retrograde Cholangiopancreatography Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.14. Norway
    • 7.5.14.1. Key Country Dynamics
    • 7.5.14.2. Competitive Scenario
    • 7.5.14.3. Regulatory Framework
    • 7.5.14.4. Reimbursement scenario
    • 7.5.14.5. Norway Endoscopic Retrograde Cholangiopancreatography Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.6. Asia Pacific
  • 7.6.1. Asia Pacific Endoscopic Retrograde Cholangiopancreatography Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.2. Japan
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Competitive Scenario
    • 7.6.2.3. Regulatory Framework
    • 7.6.2.4. Reimbursement scenario
    • 7.6.2.5. Japan Endoscopic Retrograde Cholangiopancreatography Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.3. China
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Competitive Scenario
    • 7.6.3.3. Regulatory Framework
    • 7.6.3.4. Reimbursement scenario
    • 7.6.3.5. China Endoscopic Retrograde Cholangiopancreatography Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.4. India
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Competitive Scenario
    • 7.6.4.3. Regulatory Framework
    • 7.6.4.4. Reimbursement scenario
    • 7.6.4.5. India Endoscopic Retrograde Cholangiopancreatography Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.5. South Korea
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Competitive Scenario
    • 7.6.5.3. Regulatory Framework
    • 7.6.5.4. Reimbursement scenario
    • 7.6.5.5. South Korea Endoscopic Retrograde Cholangiopancreatography Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.6. Australia
    • 7.6.6.1. Key Country Dynamics
    • 7.6.6.2. Competitive Scenario
    • 7.6.6.3. Regulatory Framework
    • 7.6.6.4. Reimbursement scenario
    • 7.6.6.5. Australia Endoscopic Retrograde Cholangiopancreatography Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.7. Thailand
    • 7.6.7.1. Key Country Dynamics
    • 7.6.7.2. Competitive Scenario
    • 7.6.7.3. Regulatory Framework
    • 7.6.7.4. Reimbursement scenario
    • 7.6.7.5. Thailand Endoscopic Retrograde Cholangiopancreatography Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.7. Latin America
  • 7.7.1. Latin America Endoscopic Retrograde Cholangiopancreatography Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7.2. Brazil
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Competitive Scenario
    • 7.7.2.3. Regulatory Framework
    • 7.7.2.4. Reimbursement scenario
    • 7.7.2.5. Brazil Endoscopic Retrograde Cholangiopancreatography Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7.3. Argentina
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Competitive Scenario
    • 7.7.3.3. Regulatory Framework
    • 7.7.3.4. Reimbursement scenario
    • 7.7.3.5. Argentina Endoscopic Retrograde Cholangiopancreatography Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.8. Middle East & Africa
  • 7.8.1. Middle East & Africa Endoscopic Retrograde Cholangiopancreatography Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.2. South Africa
    • 7.8.2.1. Key Country Dynamics
    • 7.8.2.2. Competitive Scenario
    • 7.8.2.3. Regulatory Framework
    • 7.8.2.4. Reimbursement scenario
    • 7.8.2.5. South Africa Endoscopic Retrograde Cholangiopancreatography Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.3. Saudi Arabia
    • 7.8.3.1. Key Country Dynamics
    • 7.8.3.2. Competitive Scenario
    • 7.8.3.3. Regulatory Framework
    • 7.8.3.4. Reimbursement scenario
    • 7.8.3.5. Saudi Arabia Endoscopic Retrograde Cholangiopancreatography Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.4. UAE
    • 7.8.4.1. Key Country Dynamics
    • 7.8.4.2. Competitive Scenario
    • 7.8.4.3. Regulatory Framework
    • 7.8.4.4. Reimbursement scenario
    • 7.8.4.5. UAE Endoscopic Retrograde Cholangiopancreatography Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.5. Kuwait
    • 7.8.5.1. Key Country Dynamics
    • 7.8.5.2. Competitive Scenario
    • 7.8.5.3. Regulatory Framework
    • 7.8.5.4. Reimbursement scenario
    • 7.8.5.5. Kuwait Endoscopic Retrograde Cholangiopancreatography Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Market Participant Categorization
• 8.2. Key Company Profiles
  • 8.2.1. Olympus Corporation
    • 8.2.1.1. Company overview
    • 8.2.1.2. Financial performance
    • 8.2.1.3. Product benchmarking
    • 8.2.1.4. Strategic initiatives
  • 8.2.2. CONMED Corporation
    • 8.2.2.1. Company overview
    • 8.2.2.2. Financial performance
    • 8.2.2.3. Product benchmarking
    • 8.2.2.4. Strategic initiatives
  • 8.2.3. Boston Scientific Corporation
    • 8.2.3.1. Company overview
    • 8.2.3.2. Financial performance
    • 8.2.3.3. Product benchmarking
    • 8.2.3.4. Strategic initiatives
  • 8.2.4. Medtronic PLC
    • 8.2.4.1. Company overview
    • 8.2.4.2. Financial performance
    • 8.2.4.3. Product benchmarking
    • 8.2.4.4. Strategic initiatives
  • 8.2.5. Telemed System, Inc.
    • 8.2.5.1. Company overview
    • 8.2.5.2. Financial performance
    • 8.2.5.3. Product benchmarking
    • 8.2.5.4. Strategic initiatives
  • 8.2.6. AMBU, Inc.
    • 8.2.6.1. Company overview
    • 8.2.6.2. Financial performance
    • 8.2.6.3. Product benchmarking
    • 8.2.6.4. Strategic initiatives
  • 8.2.7. FUJIFILM Holdings Corporation
    • 8.2.7.1. Company overview
    • 8.2.7.2. Financial performance
    • 8.2.7.3. Product benchmarking
    • 8.2.7.4. Strategic initiatives
  • 8.2.8. Hobbs Medical, Inc.
    • 8.2.8.1. Company overview
    • 8.2.8.2. Financial performance
    • 8.2.8.3. Product benchmarking
    • 8.2.8.4. Strategic initiatives
  • 8.2.9. Cook Group
    • 8.2.9.1. Company overview
    • 8.2.9.2. Financial performance
    • 8.2.9.3. Product benchmarking
    • 8.2.9.4. Strategic initiatives
  • 8.2.10. Streis PLC
    • 8.2.10.1. Company overview
    • 8.2.10.2. Financial performance
    • 8.2.10.3. Product benchmarking
    • 8.2.10.4. Strategic initiatives
  • 8.2.11. HOYA Group
    • 8.2.11.1. Company overview
    • 8.2.11.2. Financial performance
    • 8.2.11.3. Product benchmarking
    • 8.2.11.4. Strategic initiatives
  • 8.2.12. Karl Storz SE & Co. KG
    • 8.2.12.1. Company overview
    • 8.2.12.2. Financial performance
    • 8.2.12.3. Product benchmarking
    • 8.2.12.4. Strategic initiatives